Archford Capital Strategies LLC Has $1.26 Million Stake in Thermo Fisher Scientific Inc. (TMO)

Archford Capital Strategies LLC lessened its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,648 shares of the medical research company’s stock after selling 922 shares during the period. Archford Capital Strategies LLC’s holdings in Thermo Fisher Scientific were worth $1,258,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of TMO. Capital Research Global Investors raised its position in shares of Thermo Fisher Scientific by 29.8% in the second quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock valued at $3,019,185,000 after buying an additional 3,973,136 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Thermo Fisher Scientific by 2,058.1% in the second quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock valued at $408,620,000 after buying an additional 2,233,522 shares during the last quarter. Veritas Asset Management LLP raised its position in shares of Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after buying an additional 1,286,259 shares during the last quarter. Harbour Capital Advisors LLC raised its position in shares of Thermo Fisher Scientific by 18,197.5% in the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after buying an additional 1,194,487 shares during the last quarter. Finally, Meritage Group LP acquired a new position in shares of Thermo Fisher Scientific in the third quarter valued at approximately $201,383,000. 86.05% of the stock is owned by institutional investors and hedge funds.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $190.42 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26. Thermo Fisher Scientific Inc. has a 52 week low of $139.88 and a 52 week high of $201.20. The stock has a market cap of $76,642.25, a P/E ratio of 32.33, a price-to-earnings-growth ratio of 1.75 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. During the same period in the previous year, the firm earned $2.03 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% on a year-over-year basis. sell-side analysts predict that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at $58,016,113.98. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.49% of the stock is owned by insiders.

TMO has been the subject of a number of analyst reports. Deutsche Bank set a $226.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, October 26th. Cowen reaffirmed a “buy” rating and set a $200.00 price target on shares of Thermo Fisher Scientific in a research report on Friday, September 1st. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price target for the company in a research report on Thursday, September 7th. Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and a consensus target price of $205.21.

TRADEMARK VIOLATION NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/24/archford-capital-strategies-llc-has-1-26-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit